Oligodendroglioma Drug Discovery Service
Oligodendroglioma is a type of diffuse glioma in the central nervous system, which occurs primarily in adults. The molecular pathogenesis of oligodendroglioma has significant differences from other gliomas, which is defined by both codeletion of chromosomes 1p and 19q and mutation in isocitrate dehydrogenase type 1 (IDH1) or type 2 (IDH2). Although oligodendroglioma can be surgically resected, the fact that most of the tumors are located in the frontal lobe increases the risk of surgery. Accordingly, radiotherapy plus chemotherapy and potential immunotherapy could be used to treat oligodendroglioma. Current treatment regimens still have limitations. Creative Biolabs with years of experience has developed a range of in vitro, in vivo, and ex vivo platforms and integrated global resources and technologies, which enable researchers further explore the underlying mechanisms of oligodendroglioma and thus develop specific therapeutics such as immunotherapies.
Mechanism of Action Studies of Oligodendroglioma
Our goal is to provide you with not only best-in-class research and development services but also to support you with expertise to help you explore your project.
- IDH1 or IDH2 mutations
IDH1 and IDH2 enzymes are responsible for the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), which promotes NADPH formation and protects cells from oxidative radicals. The catalyzation of IDH1 and IDH2 participates in several cellular pathways, such as hypoxia sensing, lipogenesis, and epigenetic modification. IDH1 or IDH2 mutations are observed in oligodendroglioma, which catalyzes the α-KG to form 2-Hydroxyglutarate (2-HG). 2-HG downregulates the levels of hypoxia-inducible factor (HIF) and therefore inhibits p53 to promote tumorigenesis. Besides, 2-HG shifts the NADP/NADPH homeostasis which increases oxidative stress and leads to DNA damage and tumorigenesis. IDH1 mutation induces G-CIMP methylation, which is a glioma-specific methylation pattern at CpG islands, which causes epigenetic alterations. In addition, 2-HG is involved in the activation of the rapamycin (mTOR) pathway that is implicated in tumorigenesis.
- Codeletion of chromosomes 1p and 19q
Capicua transcriptional repressor (CIC) is involved in the inhibition of downstream growth factor signaling pathways. Far upstream element binding protein 1 (FUBP1) participates in the regulation of the cell cycle. Deletion of chromosome 1p impacts the FUBP1 gene, while the CIC gene is affected by the deletion of chromosome 19. CIC and FUBP1 mutations have been investigated to be involved in the pathogenesis of oligodendrogliomas.
Fig.1 Neural stem cells (NSCs) are the precursor cells to oligodendrocyte precursor cells (OPCs) and both may serve as the cellular origin of oligodendrogliomas. (Volovetz, 2019)
Oligodendroglioma Solutions at Creative Biolabs
The early regimen used to manage oligodendroglioma is radiotherapy plus chemotherapy. As research into molecular mechanisms has intensified, treatment modalities have begun to change. Recent studies are also considering immunotherapy as a potential option for oligodendroglioma treatment. Based on years of research experience in neuroscience and first-in-class technologies, Creative Biolabs provides one-stop solutions for oligodendrogliomas studies to further explore the mechanisms and develop novel immunotherapies. We provide in vitro, in vivo, and ex vivo services with stable oligodendroglioma cell cultures, brain slices, and dependable animal models, as well as discovery services for drug screening and development services for MoA studies. Our platforms studying brain tumors are led by professional scientists and recognized academics with advanced technologies and tools, which enable researchers to collect and analyze real-time and accurate data and enhance the process of your oligodendroglioma research projects.
Directly contact us for more detailed information about preclinical oligodendroglioma drug discovery solutions.
Reference
- Volovetz, J.; et al. Origin and development of oligodendroglioma. Oligodendroglioma. 2019: 79-87.
